Adults living with Alzheimer’s-related dementia now have a second FDA-approved drug for agitation, and for the first time, one that is not an antipsychotic. The Food and Drug Administration cleared an expanded use for Auvelity, a combination of dextromethorphan hydrobromide and bupropion hydrochloride extended-release, on April 30, 2026. The decision gives clinicians and caregivers a treatment option that sidesteps the well-documented metabolic and mortality risks tied to antipsychotic medications in elderly patients with dementia.
Why a non-antipsychotic option changes prescribing calculations
Until today, the only FDA-approved drug for agitation associated with Alzheimer’s dementia was Rexulti (brexpiprazole), an atypical antipsychotic that the agency approved in 2023. Antipsychotics as a class carry a boxed warning about increased mortality risk in elderly dementia patients, a concern that has made many prescribers and families reluctant to use them despite the severity of agitation symptoms. That tension between clinical need and safety profile has defined dementia-agitation care for years.
With Auvelity, the FDA is now authorizing a different path. In its latest communication on dementia-related agitation, the agency described Auvelity as the first non-antipsychotic treatment for this indication, underscoring that the drug does not fall into the class that has triggered longstanding safety worries. That distinction is likely to resonate in memory clinics and long-term care facilities where clinicians have often relied on off-label antipsychotic regimens only after behavioral interventions failed.
Auvelity’s clearance introduces a different pharmacological mechanism. Because the drug combines an NMDA receptor antagonist with a norepinephrine-dopamine reuptake inhibitor rather than acting on dopamine D2 receptors the way antipsychotics do, it avoids the metabolic side-effect profile, including weight gain, glucose dysregulation, and cardiovascular strain, that antipsychotics can produce. The practical question now is whether prescribers will reach for Auvelity first in patients who already carry cardiovascular or metabolic comorbidities, conditions common in elderly populations. If they do, early insurance claims data over the next 12 months should show a measurable shift toward Auvelity in that subgroup, offering a real-world test of how quickly a non-antipsychotic alternative reshapes prescribing patterns.
ADVANCE and ACCORD trial data behind the FDA decision
The agency based its decision on evidence from two clinical programs. The first, known as ADVANCE, is registered on ClinicalTrials.gov under identifier NCT03226522 and includes posted results with prespecified endpoints, participant flow, and baseline characteristics. The second, ACCORD, is a randomized-withdrawal study registered under identifier NCT04797715. A peer-reviewed analysis of the ACCORD trial published through ScienceDirect provides additional methodological detail, including hazard ratios for time-to-relapse, adverse-event rates, and subgroup analyses that go beyond what the FDA summary or trial registry alone contain.
Together, the two studies tested whether Auvelity could reduce agitation in adults with Alzheimer’s dementia and whether that benefit held up over time once the drug was withdrawn. In ADVANCE, investigators focused on change from baseline in standardized agitation scales over a fixed treatment period, while tracking safety events typical for elderly populations, such as falls, infections, and cardiovascular complications. The posted results show that patients receiving Auvelity experienced greater reductions in agitation scores than those on placebo, with separation between the groups emerging early in treatment and persisting through the primary endpoint window.
The ACCORD design, a relapse-prevention framework, is particularly telling: patients who responded to the drug during an open-label phase were then randomized to continue treatment or switch to placebo, and the study measured how quickly agitation returned. That design addresses a common criticism of short-term efficacy trials by testing durability of response. In ACCORD, time-to-relapse favored those who stayed on Auvelity, suggesting that continued dosing helps maintain behavioral stability rather than simply producing a transient calming effect. The randomized-withdrawal structure also allowed investigators to observe whether discontinuation led to rebound agitation or unexpected safety signals, issues of particular concern when treating frail older adults.
Axsome Therapeutics, the drug’s manufacturer, disclosed the FDA’s decision in a Form 8-K filing with the Securities and Exchange Commission on April 30. The filing included the regulator’s letter and outlined the company’s planned commercial rollout, including updates to promotional materials and timelines for educating prescribers in neurology, psychiatry, and geriatric medicine. The updated prescribing information, including contraindications and adverse-event tables, is now available through DailyMed, the National Library of Medicine’s public drug-label repository, giving clinicians access to the same label language the FDA reviewed.
Open questions about cost, access, and comparative performance
Several gaps in the evidence will shape how quickly Auvelity reaches patients. No independent cost-effectiveness analysis comparing Auvelity to Rexulti or to off-label antipsychotic use has been published. Formulary decisions by Medicare Part D plans and commercial insurers will depend heavily on such analyses, and until they appear, prior-authorization barriers could slow adoption regardless of the drug’s safety advantages. Pharmacy and therapeutics committees will have to extrapolate from trial data, projected utilization, and negotiated rebates to decide where Auvelity sits on tiered formularies.
The FDA’s announcement did not include direct comparative efficacy data between Auvelity and Rexulti. The two drugs were studied in separate trial programs with different designs, endpoints, and patient populations, which makes head-to-head conclusions impossible from existing evidence. Clinicians will need to weigh each drug’s safety profile against individual patient risk factors without a clear regulatory signal about which performs better in a given subgroup. For some patients, especially those with a history of psychosis or severe behavioral disturbance, an antipsychotic may still be favored; for others with diabetes, obesity, or cardiovascular disease, a non-antipsychotic mechanism may be more appealing.
Post-marketing surveillance will also matter. The clinical trials that supported approval enrolled defined populations under controlled conditions. Real-world adherence, side-effect rates in patients with multiple comorbidities, and long-term outcomes in nursing-home settings remain unmeasured. Nursing facilities often rely on overburdened staff and variable nonpharmacologic interventions, factors that can influence both the perceived need for medication and the risk of adverse events such as falls or delirium. Registries, claims analyses, and FDA-mandated safety studies will be critical to understanding whether Auvelity’s benefits in trials translate into meaningful improvements in quality of life and caregiver burden outside of research settings.
Another unresolved question is how regulators and professional societies will incorporate Auvelity into treatment algorithms. Existing practice guidelines for behavioral and psychological symptoms of dementia emphasize environmental and behavioral strategies first, with medications reserved for severe or dangerous agitation. The emergence of a non-antipsychotic option could prompt revisions that more clearly distinguish between pharmacologic classes and outline when a drug like Auvelity should be tried before, or instead of, an antipsychotic. Until such guidance is updated, prescribing patterns are likely to vary widely between institutions and specialties.
For families and caregivers, the approval may offer cautious optimism. Agitation can manifest as pacing, verbal outbursts, or physical aggression, straining relationships and sometimes forcing earlier placement in long-term care. A medication that reduces those behaviors without the same mortality warning attached to antipsychotics may be seen as a safer compromise when non-drug strategies are not enough. At the same time, advocates are likely to stress that no pill can replace adequate staffing, caregiver training, and supportive environments, and that medications-antipsychotic or not-should be used at the lowest effective dose for the shortest necessary duration.
As Auvelity moves from regulatory approval into everyday practice, the central test will be whether it changes outcomes that matter most to patients and families: fewer crises, less distress, and the ability to remain safely at home or in less restrictive care settings. The FDA’s decision, grounded in ADVANCE and ACCORD, opens that possibility. The next several years of real-world data, reimbursement decisions, and guideline updates will determine how fully the promise of a non-antipsychotic option is realized in the lives of people living with Alzheimer’s dementia.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
